Clinical trials: sponsored by Canadian Cancer Trials Group
Ovarian Cancer
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 5132 in treating patients who have metastatic or…
- Trial name
- NCT00003892
- Testing
- ISIS 5132
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 22 people
- Sponsor
- NCIC Clinical Trials Group
Leukemia
Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fludarabine in treating patients who have chronic…
- Trial name
- NCT00049075
- Testing
- fludarabine phosphate
- Where
- 34 sites in Canada, France
- Volunteers
- 128 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small…
- Trial name
- NCT00002583
- Testing
- cisplatin, vinorelbine ditartrate
- Where
- 155 sites in United States, Canada
- Volunteers
- 482 people
- Sponsor
- NCIC Clinical Trials Group
Chronic Myeloproliferative Disorders, Leukemia
Treatment for Chronic Pain in Patients With Advanced Cancer
RATIONALE: Different drug formulations and combinations of drugs may help patients with chronic pain live more comfortably. It is not yet known which regimen is most effective for chronic pain.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003687
- Testing
- dextromethorphan hydrobromide, morphine sulfate
- Where
- 4 sites in Canada
- Volunteers
- 87 people
- Sponsor
- NCIC Clinical Trials Group
Precancerous/Nonmalignant Condition, Prostate Cancer
Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia
RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Vitamin E, selenium, and soy protein may be effective in preventing the development of prostate…
- Trial name
- NCT00064194
- Testing
- selenium, soy protein isolate, vitamin E
- Where
- 3 sites in Canada
- Volunteers
- 310 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002633
- Testing
- bicalutamide, buserelin, flutamide
- Where
- 15 sites in Canada
- Volunteers
- 361 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer
RATIONALE: Marimastat may stop the growth of lung cancer by stopping blood flow to the tumor. It is not yet known if marimastat is an effective treatment for small cell lung cancer.
- Trial name
- NCT00003011
- Testing
- marimastat
- Where
- 38 sites in Canada
- Volunteers
- 555 people
- Sponsor
- NCIC Clinical Trials Group
Pain, Prostate Cancer
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain.
- Conditions
- Pain, Prostate Cancer, Quality of Life
- Trial name
- NCT00003232
- Testing
- clodronate disodium, mitoxantrone hydrochloride, prednisone
- Where
- 21 sites in Canada
- Volunteers
- 227 people
- Sponsor
- NCIC Clinical Trials Group
Pulmonary Complications, Quality of Life
Theophylline in Treating Cancer Patients With Shortness of Breath
RATIONALE: Theophylline may help to relieve shortness of breath in patients who have cancer. It is not yet known whether theophylline is more effective than no further treatment for shortness of breath.
- Conditions
- Pulmonary Complications, Quality of Life, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003684
- Testing
- theophylline, quality-of-life assessment
- Where
- 4 sites in Canada
- Volunteers
- 3 people
- Sponsor
- NCIC Clinical Trials Group
Fatigue, Lung Cancer
Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer
RATIONALE: Radiation therapy may relieve symptoms in patients with non-small cell lung cancer. It is not yet known which regimen of radiation therapy is most effective in relieving symptoms in patients with non-small cell lung…
- Conditions
- Fatigue, Lung Cancer, Nausea and Vomiting, Pain
- Trial name
- NCT00003685
- Testing
- fatigue assessment and management, nausea and vomiting therapy, pain therapy
- Where
- 21 sites in Canada
- Volunteers
- 230 people
- Sponsor
- NCIC Clinical Trials Group
Oral Complications, Quality of Life
Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids
RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition.
- Trial name
- NCT00003686
- Testing
- pilocarpine hydrochloride
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- NCIC Clinical Trials Group
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Exemestane may be effective in preventing the development of breast cancer by decreasing estrogen…
- Trial name
- NCT00066586
- Testing
- exemestane
- Where
- 12 sites in United States, Canada
- Volunteers
- 98 people
- Sponsor
- NCIC Clinical Trials Group
Pancreatic Cancer
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer…
- Trial name
- NCT00026338
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 173 sites in United States, Argentina and 17 more
- Volunteers
- 569 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for…
- Trial name
- NCT00238316
- Testing
- letrozole
- Where
- 10 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- NCIC Clinical Trials Group
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00028743
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 28 sites in Canada
- Volunteers
- 819 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002678
- Testing
- dexamethasone, melphalan, prednisone
- Where
- 37 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- NCIC Clinical Trials Group
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00354302
- Testing
- calcium carbonate, calcium citrate, cholecalciferol
- Where
- 13 sites in Canada
- Volunteers
- 497 people
- Sponsor
- NCIC Clinical Trials Group
Lymphoma
Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- IDEC-C2B8 (NCT00064116)
- Testing
- rituximab, CHOP regimen
- Where
- 25 sites in Canada
- Volunteers
- 824 people
- Sponsor
- NCIC Clinical Trials Group